Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Thinking Long-Term, Novo Ventures Finds Itself On A Hot Streak Of Quick Exits

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite a strategy that encourages holding stakes when other firms might sell, the evergreen fund has been generating quick returns.

You may also be interested in...

With $30 Million Series B In Hand, Elevation Prepares To Take Inhalable COPD Drug Up To Phase III

The two-tranche financing, backed 50% by new investor Novo Ventures, will enable the private firm to evaluate early partnering opportunities from a position of financial stability.

Reata's $450 Million Up-Front Haul Sets A Record But Remains An Outlier

In late September, Reata Pharmaceuticals Inc. dealt its Phase IIb chronic kidney disease candidate bardoxolone to Abbott Laboratories Inc., and the $450 million down payment easily dwarfs those on other deals around development-stage drug candidates, going back as far as the eye can see.

Abbott Pays $450MM Up-Front For Rights To Reata's CKD Drug

The Big Pharma would gain ex-U.S. rights to the potentially disease-modifying treatment for chronic kidney disease, excluding some Asian markets.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts